Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with <i>M. bovis</i> BCG or Other Therapies by Inmaculada Ruiz-Lorente, Lourdes Gimeno, Alicia López-Abad, Pedro López Cubillana, Tomás Fernández Aparicio, Lucas Jesús Asensio Egea, Juan Moreno Avilés, Gloria Doñate Iñiguez, Pablo Luis Guzmán Martínez-Valls, Gerardo Server, Belén Ferri, José Antonio Campillo, María Victoria Martínez-Sánchez, Alfredo Minguela

“…The HLA-B −21M/T genotype was an independent predictive parameter of the progression-free survival (HR = 2.08, <i>p</i> = 0.01) and the OS (HR = 2.059, <i>p</i> = 0.039) of BC patients treated with BCG, together with age and tumor histopathologic characteristics. …”
Get full text

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights by Juan Li, Xuan Wang, Li Zhou, Jun Guo, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoting Wei, Xinan Sheng, Siming Li, Zhihong Chi, Lili Mao, Bin Lian, Xieqiao Yan, Yan Kong, Caili Li, Xiangyong Gu, Binlei Liu, Hui Tian, Han Hu

“…A phase III clinical trial is ongoing in China (NCT05868707).Conclusions OH2 oncolytic virotherapy exhibited a favorable safety profile without dose-limiting toxicities (DLTs) and demonstrated durable antitumor efficacy in patients with melanoma, especially in those who had progressed on anti-PD-1 treatment.Trial registration number ClinicalTrials.gov identifier NCT04386967.…”
Get full text

Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation by Meng Zhang, Meng Zhang, Xiaomei Zhang, Xiaomei Zhang, Jiaxi Wang, Wenyi Lu, Xia Xiao, Hairong Lyu, Xiaoyuan He, Yedi Pu, Juanxia Meng, Cuicui Lyu, Xinping Cao, Mingfeng Zhao, Mingfeng Zhao

“…However, 2 patients withdrew from the study due to rapid disease progression. 12 participants received donor-derived CLL-1 CAR-T cells and were categorized into 3 groups based on the dosage of infused CAR-T cells dose (Group A:0.5×106/kg, Group B:1×106/kg, Group C:1.5×106/kg). …”
Get full text

Reflecting on the impact of the COVID pandemic on patient management and its subsequent influence on long-term outcomes: a case–control study in the field of esophago-gastric cance... by Mohamed Alasmar, Nadia Matias, Norah Ali M. Alhamed, Omneya Alwani, Brogan Rudge, Terngu David Moti, Muhammad Ossama Yassin Abdelwahab, Jennifer Stockton, Charef Raslan, Jess Cairney-Hill, Mohammad Altarawni, Bilal Alkhaffaf, on behalf Greater Manchester Oesophago-Gastric Service

“…Additionally, we found an increased deviation from initial curative to palliative intent in the P2 group (6.4% changed in P2 vs 2.2% in PP and 3.5% in P2) primarily driven by disease progression. A further significant observation was the emergence of more aggressive tumour characteristics, particularly in the P2 group, albeit without a statistically significant difference in two-year overall survival rates among the groups (p-value 0.31). …”
Get full text

FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial by Laith Alrubaiy, Rachel Cooney, Tariq Iqbal, Mohammed Nabil Quraishi, Susan Manzoor, Christopher Quince, Palak J Trivedi, Andrew D Beggs, Alexandra Vince, Chris Weston, Benjamin Mullish, Sahida Shabir, Nicola Jackson, Anna Rowe, Victoria Homer, Willem van Schaik, Peter Rimmer, Sarah Al-Shakhshir, Arzoo Patel, Derick Gyimah, Miriam Hares, Elena Efstathiou

“…However, the longevity of such changes and the impact on markers of disease activity and disease progression have not been studied. The aim of this clinical trial is to determine the effects of repeated FMT as a treatment for PSC-IBD.Methods and analysis FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO) is a phase IIa randomised placebo-controlled trial to assess the efficacy and safety of repeated colonic administration of FMT in patients with non-cirrhotic PSC-IBD. …”
Get full text

Using multiomic integration to improve blood biomarkers of major depressive disorder: a case-control studyResearch in context by Amazigh Mokhtari, El Chérif Ibrahim, Arnaud Gloaguen, Claire-Cécile Barrot, David Cohen, Margot Derouin, Hortense Vachon, Guillaume Charbonnier, Béatrice Loriod, Charles Decraene, Ipek Yalcin, Cynthia Marie-Claire, Bruno Etain, Raoul Belzeaux, Andrée Delahaye-Duriez, Pierre-Eric Lutz

“…Importantly, they also demonstrated that performance progressively increased with the number of molecular datasets considered. …”
Get full text

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer by Ram Patel, John Mathews, Caroline Hamm, Swati Kulkarni, Rasna Gupta, Tarquin Opperman, John Dean Chiong, Abdullah Nasser

“…Landmark trials have demonstrated a comparable progression-free survival (PFS) across CDK4/6 inhibitors, but the overall survival (OS) outcomes have varied. …”
Get full text

Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control by Helena Escuin-Ordinas, Ignacio Melero, Marisol Quintero, Jose Luis Perez-Gracia, Maite Alvarez, Maria E Rodriguez-Ruiz, Miguel F Sanmamed, Paloma Sanchez-Mateos, Inmaculada Rodríguez López, Irantzu Serrano-Mendioroz, Celia Barrio-Alonso, Eneko Garate-Soraluze, Victor Diaz Pascual, Leire Arbea Moreno

“…Injection of BO-112 into the tumor lesion receiving radiation achieved excellent control of the treated tumor and modest delays in contralateral tumor progression. Local effects were associated with more prominent infiltrates of antitumor cytotoxic tumor lymphocytes (CTLs). …”
Get full text

Sex and outcomes of patients with microsatellite instability-high and BRAF V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors by Michael Hoffmeister, Hermann Brenner, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Julien Taieb, David Tougeron, Robyn L Ward, Marco Vitellaro, Thierry André, Pierre Laurent-Puig, Jitendra Jonnagaddala, Francesca Bergamo, Raghav Sundar, Claire Gallois, Michael J Overman, Jakob Nikolas Kather, Lisa Salvatore, Romain Cohen, Rossana Intini, Priya Jayachandran, Miriam Koopman, Javier Ros, Marwan Fakih, Vincenzo Nasca, Giacomo Mazzoli, Jeanine M L Roodhart, Filippo Ghelardi, Elena Elez, Durgesh Wankhede, Marta Ligero, Joseph Zhao, Koen Zwart, Jeroen Derksen, Nicholas Hawkins, Javier Carmona

“…Finally, we explored two public microarray and RNA-seq datasets from patients with non-metastatic or metastatic MSI-H CRC to gain translational insights on the association between sex, BRAF status and immune contextures/ICI efficacy.Results Although no differences were observed between females and males either overall or in the BRAF wild-type cohort, male sex was associated with inferior progression-free survival (PFS) and overall survival (OS) in the BRAF mutated cohort (in multivariable models, HR for PFS: 1.79, 95% CI: 1.13 to 2.83, p=0.014, and for OS: 2.33, 95% CI: 1.36 to 3.98, p=0.002). …”
Get full text

Predictive role of SLC1A5 in neuroblastoma prognosis and immunotherapy by Jian Cheng, Miaomiao Sun, Xiao Dong, Yang Yang, Xiaohan Qin, Xing Zhou, Yongcheng Fu, Yuanyuan Wang, Jingyue Wang, Da Zhang

“…Conclusion SLC1A5 plays a pivotal role in neuroblastoma by promoting tumor progression and shaping an immunosuppressive microenvironment. …”
Get full text

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy by Coraline Radermecker, Pascale Hubert, Patrick Roncarati, Stephanie Demoulin, Charlotte Pilard, Marie Ancion, Celia Reynders, Thomas Lerho, Diane Bruyere, Alizee Lebeau, Margot Meunier, Marie-Julie Nokin, Elodie Hendrick, Olivier Peulen, Philippe Delvenne, Michael Herfs

“…Regarding its role in cancer development/progression, paradoxical results exist in the literature and it is still unclear whether HMGB1 mainly acts as an oncogene or a tumor suppressor.Methods HMGB1 expression was first assessed in tissue specimens (n=359) of invasive breast, lung and cervical cancer and the two distinct staining patterns detected (nuclear vs cytoplasmic) were correlated to the secretion profile of malignant cells, patient outcomes and the presence of infiltrating immune cells within tumor microenvironment. …”
Get full text

Clinical and ultrasound characteristics in patients with sars-cov-2 pneumonia, associated with hospitalization prognosis. e-covid project by Noemí Fàbrega Ramon, Marta Ortega Bravo, Gerard Torres Cortada, Joaquim Sol Culleré, Mònica Solanes Cabús, Jose María Palacín Peruga

“…This research is crucial to provide a deeper understanding of how these pre-existing ultrasound patterns related to disease progression influence the medical treatment. Methods The objective of the study is to generate predictive models of lung ultrasound patterns for the prediction of lung areas characteristics associated with hospitalizations and admissions to the Intensive Care Unit (ICU) associated with COVID-19 disease, using ultrasound, sociodemographic and medical data obtained through the computerized medical history. …”
Get full text

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan by Eisaku Miyauchi, MD, PhD, Makoto Nishio, MD, PhD, Kadoaki Ohashi, MD, PhD, Atsushi Osoegawa, MD, PhD, Eiki Kikuchi, MD, PhD, Hideharu Kimura, MD, PhD, Yasushi Goto, MD, PhD, Junichi Shimizu, MD, PhD, Hiroshige Yoshioka, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Nobuyuki Katakami, MD, PhD, Masahide Oki, MD, PhD, Takashi Kijima, MD, PhD, Kenichi Chikamori, MD, PhD, Kazumi Nishino, MD, PhD, Yuki Kobayashi, MS, Asako Miwa, BA, Misa Tanaka, MS, Akihiko Gemma, PhD

“…Secondary end points included overall survival (OS), progression-free survival (PFS), and safety in select subgroups, including the IMpower133-unlike (i.e., Eastern Cooperative Oncology Group performance status 2 or more, interstitial lung disease, autoimmune disease) versus IMpower133-like groups. …”
Get full text

Association between the composite dietary antioxidant index and non-alcoholic fatty liver disease: evidence from National Health and Nutrition Examination Survey 2005–2016 by Yidian Fu, Yidian Fu, Chao Jiang, Zonglin Li, Xiangyun Shi, Peiyuan Lv, Peiyuan Lv, Jingbo Zhang

“…ImportanceOxidative stress contributes to the progression of non-alcoholic fatty liver disease (NAFLD). …”
Get full text

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer by Lei Wang, Yafei You, Wenzhuo He, Yu Hou, Lan Li, Li Wang, Chang Jiang, Jiahong Yi, Yaoxiong Xia, Liangping Xia

“…However, the efficacy and safety of pralsetinib in real world has rarely been reported.Materials and methodsThis study reviewed the efficacy and safety of pralsetinib in RET fusion-positive NSCLC patients between March 2021 and December 2021. Progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and log-rank test. …”
Get full text

Factors associated with non-response and nutritional status of non-responders at 6-month post-discharge: a cohort study nested in a MUAC-based nutrition programme for acutely malno... by Maguy Daures, Jérémie Hien, Cécile Cazes, Rodrigue Alitanou, Laure Saillet, Benjamin Séri, Ahmad Ag Mohamed Aly, Oumarou Maidadji, Atté Sanoussi, Aboubacar Mahamadou, Mathias Altmann, Kevin Phelan, Renaud Becquet, Susan Shepherd

“…As efforts to expand MUAC-based programming progress, adapting exit criterion and/or providing additional food supplementation with smaller daily ration for children with risk factors discussed here may help improve programme efficiency without adding to the cost of treatment.…”
Get full text

Predictors of developing severe COVID-19 among hospitalized patients: a retrospective study by Hussain Abduljaleel Alkhalifa, Ehab Darwish, Zaenb Alsalman, Aman Alfaraj, Abdullah Alkhars, Fatimah Alkhalifa, Mohammed Algaraash, Ahmed Mohammed Elshebiny, Emad Alkhoufi, Khaled Mohamed Amin Elzorkany

“…As the severity of SARS-CoV-2 infection varies among individuals, elucidating risk factors for severe COVID-19 is important for predicting and preventing illness progression, as well as lowering case fatality rates. …”
Get full text

Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study by Jing Wang, Tao Zhang, Lei Zhao, Min Jin, Pindong Li, Shengli Yang, Hong Ma, Zhenyu Lin, Junli Liu, Hongli Liu, Kunyu Yang, Dandan Yu, Jianli Hu, Jun Xue, Mingxia Cheng, Chuying Huang

“…Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. …”
Get full text

Endogenous sex hormone levels are associated with the revised Framingham Stroke Risk Profile in postmenopausal women: a longitudinal study in a Swedish cohort by Kristin Ottarsdottir, Åsa Tivesten, Claes Ohlsson, Ying Li, Margareta Hellgren, Ulf Lindblad, Bledar Daka

“…Methods This is an observational cross-sectional study on the Vara-Skövde cohort, a Swedish population-based study for longitudinal surveillance of the development and progress of type 2 diabetes and hypertension. The participants were physically examined in 2002–2005 and sex hormones were analysed with liquid chromatography-tandem mass spectrometry assay (LC-MS/MS). …”
Get full text

Your period and your pregnancy, a cohort study of pregnant patients investigating the associations between menstruation and birth outcomes in Australia: study protocol by Miranda Davies-Tuck, Billie Bradford, Adrienne Gordon, Beverley Vollenhoven, Kirsten Rebecca Palmer, Kirstin Tindal, Caroline E Gargett, Fiona Cousins, Stacey Ellery

“…The majority of stillbirths occur in the preterm period, yet there are few interventions targeting this period, and progress to reduce stillbirth rates remains slow. Placental dysfunction is a major contributor to stillbirth, particularly, preterm stillbirth. …”
Get full text